Hazard Characterisation

Our hazard assessments, generally based on in-depth searches of the scientific literature, aim to define the dose-response for all routes of each of a chemical’s toxicological propensities, for example its carcinogenicity, genotoxicity, or ability to disrupt reproduction.

We summarise all of the available data in a transparent format, taking into account the needs of our clients – for example, if there is a specific structure or format required to comply with a particular regulation.

As experienced risk assessors ourselves we are well placed to ensure that our hazard characterisation – the potential to induce a harm - provides the best possible platform the available data (and budget) will allow for any subsequent risk assessment, a judgement as to whether those harms will actually be seen in a specific circumstance.

Routes of Administration

Hazard characterisation graphic

Screening assessments

Often, we are asked to assess several compounds that could be of potential health risk to a patient. We have developed a “screening” process where we can prioritise those substances that are more likely to result in a health risk. Compounds present at very low levels, or without inherent toxic hazards, can, with appropriate justification, be excluded from further more detailed and expensive toxicological risk assessment.

(Q)SAR

More and more computational models are being developed to link a particular toxicological hazard with a chemical structure. This is called (Quantitative) Structure-Activity Relationship ((Q)SAR) modelling. When we are faced with a data-poor chemical, we routinely use (Q)SAR to generate predictions and identify possible areas of concern, or endpoints worthy of further investigation. Even the most sophisticated models still currently require a sanity check and bibra’s experienced toxicologists are ideally placed to provide it.

Safety Benchmarks

Often, a toxicological hazard characterisation is the major first step on a pathway leading to a health-based guidance value. Such a value is an estimate of the maximum exposure, generally qualified by route (parenteral, inhalation, oral or dermal), that will pose no significant threat to human health. It will usually be based on data from laboratory animal experiments, adjusted to account for the likely differences in how humans and the other species (usually a rodent) is likely to respond to chemicals in general or (much more rarely) to that specific test chemical.

Some industries we work in

E-cigarettes + NDDs

We provide valuable advice on toxicological issues relating to e-cigarettes (and other nicotine delivery devices), and can support your regulatory submissions within the scope of EU TPD, UK TRPR and the US FDA PMTA.

Smoke whisps

Pharmaceuticals

Our team is adept at preparing critical toxicological reports - we regularly provide assessments of novel or unexpected impurities, excipients and other intentionally-added substances, and extractables and leachables.

Pharma tile 800w

Medical Devices

We are adept at conducting biocompatibility assessments and biological safety evaluations of medical devices in compliance with ISO 10993, FDA and European guidelines, to help bring your device to market.

Plaster 3

Some of our case studies in this area

Hazard characterisation of several e-liquid ingredients

Case study

The client is required to provide regulatory authorities with up-to-date toxicological information related to the ingredients used in their products. Bibra were provided with a list of several substances and asked to produce a hazard review (considering the requirements of the European Tobacco Products Directive, TPD2) for each.

Get in touch

Please read our Privacy Policy here

*mandatory fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contact us